We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Two Companies Get Warning Letters Over Misbranded Drugs, Product Specification

Two Companies Get Warning Letters Over Misbranded Drugs, Product Specification

October 28, 2016

Ajes Pharmaceuticals and Positive Power Nutrition have been hit with warning letters after the FDA conducted inspections.

Positive Power Nutrition got a warning letter for its 11 products due to claims made, including claims that the products help the body heal from varicose veins; protect against cardiovascular disease; fight bone loss, chronic fatigue, depression, constipation, ringing in the ears, and pernicious anemia; and are found to aid in the healing of gastritis, liver disorders, asthma, and anemia.

The products fail to bear adequate directions for their intended use, and there is no data to prove that the claims made by Positive Power Nutrition for their medications are true.

Ajes Pharmaceuticals failed to establish product specifications for the identity, purity, strength, and composition of its finished batches of dietary supplements.

In its response Ajes stated that it had taken measures to ensure finished product testing and to ensure specifications were met for identity, purity, strength and composition, but did not provide complete finished product specifications and acceptance criteria for the products.

In addition, Ajes did not collect and hold reserve samples of each lot of packaged and labeled dietary supplements. Ajes’ response also does not contain sufficient information to determine if the products meet its specifications.

The CCDS serves as the basis for prescribing a medication but also for global advertising and promotional activities. In some countries, notably the U.S., promotional claims that do not conform to approved-labeling can render the product misbranded. It’s high time you sharpened your CCDS-writing skills. Order our Perfecting Your Company Core Data Sheets webinar cd to help you do just that.

View today's stories

Pharmaceuticals Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing